Please login to the form below

Not currently logged in
Email:
Password:

Merck's Saphris cleared for new uses

Merck has won US Food and Drug Administration approval of new indications for its atypical antipsychotic Saphris

Merck has won US Food and Drug Administration (FDA) approval of new indications for its atypical antipsychotic Saphris (asenapine).

The sublingual tablets may now be marketed for the treatment of schizophrenia in adults, as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, and as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.

Saphris won its initial US approval in mid-August of last year for the acute treatment of schizophrenia in adults and as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults.

Earlier this month, the drug, which Merck markets as Sycrest outside the US, won approval throughout the EU for treating moderate to severe manic episodes in adult patients with bipolar I disorder. However, European authorities declined to approve the drug as a treatment of schizophrenia.

Saphris was acquired in late-stage clinical development by Schering-Plough as part of the company's 2007 merger with Organon International. Merck and Schering-Plough merged last year.

Merck has not yet reported sales figures for the recently launched drug.

8th September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Article
How will COVID-19 affect uptake of vaccinations against other diseases?...
Top 10 Reasons Why Virtual Collaboration and Medical Education Will Persist in the New Normal
Even after the pandemic is long behind us, virtual collaboration will become mainstay in Pharma....
Podcast
Living With Chronic Illness (Series one)...

Infographics